Ciprofloxacin/Celecoxib Combination in Patients With ALS

NCT ID: NCT04090684

Last Updated: 2022-02-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-12-09
• Study Completion Date: 2022-01-20

Brief Summary

This is an open label, off label study, to provide interested ALS patients with Ciprofloxacin/Celecoxib fixed dose combination, while assessing safety and tolerability, routine disease progression measures (ALSFRS-R and Vital Capacity).

Detailed Description

Patients will be prescribed a fixed dose combination of Ciprofloxacin and Celecoxib to be taken twice daily, and will be monitored for safety and tolerability. Additionally, routine progression measures will be assessed.

Conditions

ALS (Amyotrophic Lateral Sclerosis)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Fixed dose Ciprofloxacin and Celecoxib

Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day

Group Type: EXPERIMENTAL

Fixed dose combination Ciprofloxacin/Celecoxib

Intervention Type: DRUG

Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day

Interventions

Fixed dose combination Ciprofloxacin/Celecoxib

Fixed dose Ciprofloxacin and Celecoxib capsule to be taken twice daily, total dose 748mg/day

Intervention Type: DRUG

Other Intervention Names

PrimeC

Eligibility Criteria

Inclusion Criteria

1. Able to comprehend and willing to sign an Informed Consent Form (ICF)

2. Males or females between the ages of 18 and 75 years of age, inclusive

3. Diagnosis of familial or sporadic ALS (defined as meeting the possible, laboratory-supported probable, probable, or definite criteria for a diagnosis of ALS according to the World Federation of Neurology El Escorial criteria) less than 5 years prior to baseline

4. Patients may be on Riluzole and/or Edaravone; 30 days of stable use is required to make safety assessments more reliable

5. Upright Forced Vital Capacity (FVC) ≥ 50% of predicted for age, height and sex at screening

6. Patient is able to swallow tablets/ capsules

7. A caregiver (if one is needed)

8. Female patients must be post-menopausal (≥ 1 year) OR sterilized, OR if of childbearing potential (i.e., females who have had their first period unless they are anatomically and physiologically incapable to become pregnant), must have a negative pregnancy test, and agree to use contraceptive drugs or devices (e.g., diaphragm plus spermicide, or oral contraceptives) for the duration of the study and 10 weeks after the last treatment dose AND require male partners to use a condom during sexual intercourse

Exclusion Criteria

1. A past history of adverse reaction/hypersensitivity to either NSAIDs, celecoxib or fluoroquinolones, ciprofloxacin

2. Any known clinically significant abnormal gastric mucosal initial gastroscopic of an erosion, ulcer or tumor or/and GI disorder

3. Known history of impaired renal function.

4. Known or suspected congestive heart and/or coronary heart disease, previous history of myocardial infarction, uncontrolled arterial hypertension, or rhythm abnormalities requiring permanent treatment

5. Known history of QT/QTc prolongation, Torsade de pointes (TdP) (e.g. heart failure, hypokalemia, family history of Long QT syndrome) and the use of concomitant medications that prolong the QT/QTc interval.

6. Known or suspected diagnosis or family history of epilepsy

7. Presence at screening of any medically significant cardiac, pulmonary, musculoskeletal, or psychiatric illness that might interfere with the patient's ability to comply with study procedures or that might confound the interpretation of clinical safety data, including, but not limited to:

1. Mean systolic blood pressure >180 mm Hg; mean diastolic blood pressure >100 mm Hg (measurements taken after few min rest) that persist on 3 successive measurements taken at least 2 minutes apart

2. NYHA Class II or greater congestive heart failure

3. Chronic obstructive pulmonary disease or asthma requiring daily use of bronchodilator medications

4. Poorly controlled or brittle diabetes mellitus

5. Cognitive impairment, related to ALS or otherwise, sufficient to impair the patient's ability to understand and/or comply with study procedures and provide informed consent

8. Female who is pregnant or breastfeeding or with intention of becoming pregnant during the course of the study

9. Any impairment or social circumstance that, in the opinion of the Investigator, would render the patient not suitable to participate in the study

10. Patient, patient's parent(s), or patient's legal guardian(s) is/are unable to understand the nature, scope, and possible consequences of the study

11. Patient is participating in (or plans to participate in) any other investigational drug trial, or plans to be exposed to any other investigational agent, device and/or procedure, from 30 days prior to Screening through study completion

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

NeuroSense Therapeutics Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jeremy Shefner, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Barrow Neurological Institute

Locations

Barrow Neurological Institute

Phoenix, Arizona, United States

Countries

United States

Other Identifiers

NST001

Identifier Type: -

Identifier Source: org_study_id